Characterization and immunogenicity of nanoparticle vaccines displaying embecovirus spike proteins
Biotechnology Progress, EarlyView.Virus‐like particle vaccines displaying spike proteins from OC43, HKU1 A, and HKU1 B were evaluated in mice for their ability to elicit antibodies against the spike proteins from OC43, HKU1 A, HKU1 B, and HKU1 C. Abstract Endemic human coronaviruses OC43 and HKU1 cause widespread respiratory infections and can be associated with severe illness in ...
Peter J. Halfmann +6 more
wiley +1 more source
Health disparities in chronic liver disease
Hepatology, EarlyView., 2022 Abstract The syndemic of hazardous alcohol consumption, opioid use, and obesity has led to important changes in liver disease epidemiology that have exacerbated health disparities. Health disparities occur when plausibly avoidable health differences are experienced by socially disadvantaged populations.
Ani Kardashian +3 more
wiley +1 more source
Precore/core mutation relatedness to viral reactivation in patients undergoing targeted therapy for hepatitis B virus-related hepatocellular carcinoma. [PDF]
World J Biol ChemAbdulrahman MS +4 more
europepmc +1 more source
Effect of aesthetic crown lengthening on life quality and self‐esteem: 2‐year study
Clinical Advances in Periodontics, EarlyView.Abstract Background A gummy smile can result from several factors, often leading to a disharmonious appearance and causing physical and psychological discomfort for the patient. This study aimed to evaluate changes in self‐esteem and quality of life for patients, as well as the recidivism rate, following aesthetic crown lengthening (ACL) surgery ...
Leticia S. Arroteia +7 more
wiley +1 more source
Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis
Hepatology, EarlyView., 2022 Diagram of the activation of the profibrotic and procontractile Janus kinase 2 (JAK2)/Ras homolog family member A/Rho‐kinase pathway and the inhibition of phosphorylated JAK2 by pacritinib to inhibit hepatic stellate cell activity. Abstract Background and Aims Janus kinase 2 (JAK2) signaling is increased in human and experimental liver fibrosis with ...
Sandra Torres +21 more
wiley +1 more source
Identification of novel neutralizing determinants for protection against HCV
Hepatology, EarlyView., 2022 Identification of novel neutralizing determinants for protection against hepatitis C virus. Abstract Background and Aims HCV evasion of neutralizing antibodies (nAb) results in viral persistence and poses challenges to the development of an urgently needed vaccine.
Garazi P. Alzua +12 more
wiley +1 more source
Generating hepatitis B and D monitoring indicators in Germany using claims data: number of persons tested, incident and prevalent infections, 2016-2021. [PDF]
BMC Infect DisBranke L +6 more
europepmc +1 more source
Bemnifosbuvir: An HCV NS5B Inhibitor With Multiple Modes of Action
Clinical Pharmacology &Therapeutics, EarlyView.Bemnifosbuvir (BEM) is a potent, pan‐genotypic inhibitor targeting the hepatitis C virus (HCV) NS5B polymerase. Its antiviral activity was evaluated in an ascending dose phase I clinical trial involving 30 patients treated once a day for 7 days. After treatment initiation, plasma HCV RNA declined in a biphasic manner with a mean reduction of 2.3 log10 ...
Carolin Zitzmann +4 more
wiley +1 more source
Treatment and outcomes of immunotherapy related colitis and hepatitis- a multi-centre cohort study in the United Kingdom by the National Oncology Trainee Collaborative for Healthcare Research (NOTCH). [PDF]
Support Care CancerSwaminathan M +20 more
europepmc +1 more source